Valentina R. Garbarino

Valentina R. Garbarino

Auto-generated profile, based on publicly available information

Valentina R. Garbarino

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MGMitzi M. Gonzales
Mitzi M. Gonzales
VGValentina R. Garbarino
Valentina R. Garbarino
TKTiffany F. Kautz
Tiffany F. Kautz
JPJuan Pablo Palavicini
Juan Pablo Palavicini
MLMarisa Lopez-Cruzan
Marisa Lopez-Cruzan
MOMiranda E. Orr
Miranda E. Orr

1 June 2015 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
VGValentina R. Garbarino
Valentina R. Garbarino
MOMiranda E. Orr
Miranda E. Orr
KRKarl A. Rodriguez
Karl A. Rodriguez
RBRochelle Buffenstein
Rochelle Buffenstein

1 February 2019 in Pharmacological Research
Verified
Journal Article
Closed access
VGValentina R. Garbarino
Valentina R. Garbarino
LGLee Gilman
Lee Gilman
Lynette DawsLynette Daws
Lynette Daws
GGGeorgianna Gould
Georgianna Gould

20 May 2025 in Communications Medicine
Verified
Journal Article
Open access
MGMitzi M. Gonzales
Mitzi M. Gonzales
VGValentina R. Garbarino
Valentina R. Garbarino
TKTiffany F. Kautz
Tiffany F. Kautz
XSXuemei Song
Xuemei Song
MLMarisa Lopez-Cruzan
Marisa Lopez-Cruzan
DKDean Kellogg
Dean Kellogg
Rapamycin has been shown to extend lifespan and acts on pathologies underlying Alzheimer's disease and related dementias in animal models. However, rapamycin's clinical application remains underexplored. We conducted a single-site open-label phase 1 clinical trial (ClinicalTrials.gov: NCT04200911) to examine the effects of rapamycin in humans. Eligible participants were people 55-85 years old with mild cognitive impairment or early-stage dementia, which was defined as having a Global Clinical Dementia Rating Scale Score of 0.5-1. All participants received rapamycin (1 mg/day) for eight weeks. The primary aim was to evaluate rapamycin's central nervous system penetrance by assaying drug levels in the cerebrospinal fluid (CSF) before and after treatment. Secondary aims evaluated safety, cognition, Alzheimer's disease, and inflammatory biomarkers in the CSF and plasma. In ten participants (mean age 74 ± 4 years, 60% female), we find that rapamycin is not detectable in the CSF before or after treatment. After treatment, we find that twenty, mostly mild adverse events occur, systolic blood pressure and hemoglobin A1c increase, multiple erythrocyte parameters decrease, and there are no significant cognitive changes. Furthermore, we find that CSF phosphorylated tau-181 (mean change (95% confidence interval) pg/ml), 2.64 [0.70-4.59]), glial fibrillary acidic protein (6262.21 [3787.44-9373.84]), and neurofilament light (367.19 [204.28-561.61]) and plasma interferon gamma (4.37 [3.01-5.74]), interleukin 5 (0.33 [0.12-0.64]), vascular endothelial growth factor D (3741.03 [1505.98-5976.07]), soluble fms-like tyrosine kinase-1 (258.88 [89.03-428.74]) and placental growth factor (20.81 [12.38-29.25]) significantly increase (FDR-corrected p-value < 0.05). Rapamycin is not detectable in the CSF before or after treatment, but several Alzheimer's disease and inflammatory biomarkers increase after treatment. Our results highlight the need to better understand the biological effects and clinical impact of repurposing rapamycin for Alzheimer's disease.

21 October 2021 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
MGMitzi M. Gonzales
Mitzi M. Gonzales
Sudarshan KrishnamurthySudarshan Krishnamurthy
Sudarshan Krishnamurthy
VGValentina Garbarino
Valentina Garbarino
ADAli S. Daeihagh
Ali S. Daeihagh
Gregory GillispieGregory Gillispie
Gregory Gillispie
MOMiranda E. Orr
Miranda E. Orr

1 June 2013 in Southeastern Naturalist
Verified
Journal Article
Closed access
VGValentina R. Garbarino
Valentina R. Garbarino
JCJoshua Campbell
Joshua Campbell
JOJoseph O'Brien
Joseph O'Brien
HPHeather C. Proctor
Heather C. Proctor
BDBilal Dik
Bilal Dik